Bruker Corporation (NASDAQ:BRKR) Stock Has Consensus Price Target of $58.57 According to Brokerages

Shares of Bruker Corporation (NASDAQ:BRKR) have earned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $59.43.

Several research firms have weighed in on BRKR. The Goldman Sachs Group raised shares of Bruker from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, September 21st. UBS Group started coverage on shares of Bruker in a research report on Wednesday, September 9th. They set a “neutral” rating and a $65.00 price objective on the stock. Guggenheim upped their price target on Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Citigroup cut their price target on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a report on Wednesday, August 5th. Finally, Leerink Partners raised their price objective on Bruker from $60.00 to $80.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th.

Bruker Stock Up 1.7%

Bruker stock opened at $56.54 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. Bruker has a 52-week low of $32.37 and a 52-week high of $66.98. The firm has a 50 day moving average price of $58.76 and a two-hundred day moving average price of $53.34. The firm has a market cap of $8.61 billion, a price-to-earnings ratio of -80.77, a PEG ratio of 1.70 and a beta of 1.22.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same quarter in the previous year, the company earned $0.32 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts predict that Bruker will post 2.12 EPS for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Monday, September 21st were given a $0.05 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker’s dividend payout ratio (DPR) is presently -28.57%.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares in the company, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 27.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BRKR. Arizona State Retirement System grew its holdings in shares of Bruker by 0.6% during the second quarter. Arizona State Retirement System now owns 29,402 shares of the medical research company’s stock valued at $1,769,000 after buying an additional 188 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Bruker by 88.6% in the 2nd quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company’s stock worth $64,000 after acquiring an additional 498 shares during the last quarter. State of Michigan Retirement System lifted its position in Bruker by 1.9% in the 1st quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company’s stock valued at $964,000 after acquiring an additional 500 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in Bruker by 2.7% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 22,767 shares of the medical research company’s stock valued at $822,000 after acquiring an additional 600 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in Bruker by 4.9% in the 1st quarter. Cetera Investment Advisers now owns 13,184 shares of the medical research company’s stock valued at $476,000 after acquiring an additional 612 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company’s portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.